Svizera Labs Private Limited Strip Export Data — India (DGFT 2022–2026)

Name: Svizera Labs Private Limited Strip Export Records India — #5 Exporter, 35 Shipments, $1.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Strip

India Pharmaceutical Trade Intelligence

$196.8M612 Suppliers170 CountriesHS 30049099

ExportsIndia → RUSSIA26.4%India → BELGIUM12.0%

#1 Supplier: SUN PHARMACEUTICAL #1 Buyer: AO RANBAXY

Svizera Labs Private Limited — Strip Exporter #5 | $1.8M Trade Value | TransData Nexus | TransData Nexus

Svizera Labs Private Limited — Strip Exporter Profile

Indian Pharmaceutical Exporter · #5 for Strip · $1.8M export value · DGFT Verified

Svizera Labs Private Limited is the #5 Indian exporter of Strip with $1.8M in export value and 35 verified shipments. Svizera Labs Private Limited holds a 0.9% market share in Strip exports across 2 countries. The company exports 5 pharmaceutical products worth $13.7M across 3 therapeutic categories.

Svizera Labs Private Limited — Strip Export Profile: Buyers & Destinations

Svizera Labs Private Limited Strip export treemap — buyers and destination countries | TransData Nexus

Where Does Svizera Labs Private Limited Export Strip?

Country	Value	Shipments	Share
NIGERIA	$1.7M	34	94.4%
MYANMAR	$100.0K	2	5.6%

Svizera Labs Private Limited exports Strip to 2 countries. The largest destination is NIGERIA accounting for 94.4% of Svizera Labs Private Limited's Strip shipments. These destinations reflect Svizera Labs Private Limited's established distribution network and regulatory approvals in key markets.

Who Are the Top Buyers of Strip from Svizera Labs Private Limited?

What Strip Formulations Does Svizera Labs Private Limited Export?

Product Description / Formulation	Value	Shipments
12 STRIPS OF 28 TABLETS EACH OF RIFAMPICIN 150 MG/ ISONIAZID 75 MG TABLETS(6431X12)	$300.0K	6
6 STRIPS OF 28 TABLETS EACH OF RIFAMPICIN 150MG/ISONIAZID 75 MG/ PYRAZINAMIDE 400MG/ETHAMBUTOL HCL 275MG TABLETS(6431X6)	$300.0K	6
12 STRIPS OF 28 TABLETS EACH OF RIFAMPICIN 150 MG/ ISONIAZID 75 MG TABLETS (6430x12 = 77160 strips)	$150.0K	3
6 STRIPS OF 28 TABLETS EACH OF RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400MG/ETHAMBUTOL HCL 275MG TABLETS(6430x6	$150.0K	3
RIFAMPICIN 150 MG/ ISONIAZID 75 MG / PYRAZINAMIDE 400MG / ETHAMBUTOL HCL 275MG TABLETS (QTY. 6430X6 = 38580 STRIPS)	$150.0K	3
RIFAMPICIN 150 MG/ ISONIAZID 75 MG TABLETS (QTY. 6430X12 = 77160 STRIPS)	$150.0K	3
12 STRIPS OF 28 TABLETS EACH OF RIFAMPICIN 150 MG/ ISONIAZID 75 MG TABLETS (6431x12 = 77172 strips)	$100.0K	2
6 STRIPS OF 28 TABLETS EACH OF RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400MG/ETHAMBUTOL HCL 275MG TABLETS(6431x6=	$100.0K	2
12 STRIPS OF 28 TABLETS EACH OF RIFAMPICIN 150 MG/ ISONIAZID 75 MG TABLETS	$50.0K	1
6 STRIPS OF 28 TABLETS EACH OF RIFAMPICIN 150 MG/ ISONIAZID 75 MG PYRAZINAMIDE 400MG /ETHAMBUTOL HCL 275MG TABLETS	$50.0K	1

Svizera Labs Private Limited exports 16 distinct Strip formulations including tablets, capsules, syrups, and combination drugs. The top formulation is 12 STRIPS OF 28 TABLETS EACH OF RIFAMPICIN 150 MG/ ISONIAZID with 6 shipments worth $300.0K.

How Does Svizera Labs Private Limited Compare to Nearest Strip Exporters?

Exporters ranked immediately above and below #5 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
6	SRS PHARMACEUTICALS PRIVATE LIMITED	$2.7M	59	2	$45.3K
8	GUFIC BIOSCIENCES LIMITED	$1.9M	72	6	$26.4K
5	SVIZERA LABS PRIVATE LIMITED ★	$1.8M	35	2	$50.0K
2	MANEESH PHARMACEUTICALS LIMITED	$1.7M	34	6	$50.0K
3	AP WAREHOUSING AND TRADING LLP	$1.4M	28	1	$50.0K

Svizera Labs Private Limited ranks #5 among 612 Indian Strip exporters. Average shipment value of $50.0K compared to the market average of $229.4K. The closest competitors by value are SRS PHARMACEUTICALS PRIVATE LIMITED and GUFIC BIOSCIENCES LIMITED.

Which Indian Ports Ship Strip Exports?

Port	Shipments	% Share
SAHAR AIR CARGO ACC (INBOM4)	3,252	21.7%
SAHAR AIR	2,848	19.0%
Bombay Air Cargo	714	4.8%
NHAVA SHEVA SEA (INNSA1)	701	4.7%
DELHI AIR	672	4.5%
DHANNAD ICD	615	4.1%
Bombay Air	577	3.8%
DELHI AIR CARGO ACC (INDEL4)	483	3.2%

Geopolitical & Trade Policy Impact on Svizera Labs Private Limited's Strip Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Svizera Labs. The escalation of conflicts in the Middle East, particularly the 2026 Strait of Hormuz crisis, has led to significant disruptions in vital trade corridors. Shipping routes through the Red Sea and the Suez Canal have been compromised, resulting in longer transit times and increased freight costs. For instance, diversions around the Cape of Good Hope have added 10–20 days to transit times and raised freight rates by 40–50% on key India–Europe routes. (livemint.com) These disruptions pose logistical challenges for time-sensitive pharmaceutical shipments, potentially affecting Svizera's export efficiency and cost structures.

Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to expand their footprint in markets seeking alternative suppliers. Svizera Labs can capitalize on this shift by strengthening its presence in regions looking to diversify their pharmaceutical import sources. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains imperative. The FMD mandates stringent serialization and traceability requirements, necessitating investments in technology and processes to ensure compliance and maintain access to the lucrative EU market.

Svizera Labs Private Limited — Regulatory Compliance & Quality Standards

The regulatory environment for pharmaceutical exports is becoming increasingly stringent, with agencies like the U.S. Food and Drug Administration (FDA), WHO, and the European Medicines Agency (EMA) enforcing rigorous Good Manufacturing Practice (GMP) standards. Svizera Labs' previous suspension by the WHO in 2016 highlights the critical importance of maintaining compliance with these standards. The successful lifting of the suspension in 2018 demonstrates the company's commitment to quality improvement. Continuous adherence to evolving regulatory requirements is essential for sustaining market access and competitiveness.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Strip shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Svizera Labs Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 36 individual customs records matching Svizera Labs Private Limited exporting Strip, covering 16 formulations to 2 countries via 3 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 170+ countries, 2,109+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Strip

Strip

Svizera Labs Private Limited — Strip Exporter Profile

Svizera Labs Private Limited — Strip Export Profile: Buyers & Destinations

Where Does Svizera Labs Private Limited Export Strip?

Who Are the Top Buyers of Strip from Svizera Labs Private Limited?

What Is India's Total Strip Export Value and How Much Does Svizera Labs Private Limited Contribute?

What Is the Average Shipment Value for Svizera Labs Private Limited's Strip Exports?

How Does Svizera Labs Private Limited Compare to Other Indian Strip Exporters?

What Strip Formulations Does Svizera Labs Private Limited Export?

Regulatory Requirements: Exporting Strip to Key Markets

Nigeria — NAFDAC

How Does Svizera Labs Private Limited Compare to Nearest Strip Exporters?

Which Indian Ports Ship Strip Exports?

Geopolitical & Trade Policy Impact on Svizera Labs Private Limited's Strip Exports

Svizera Labs Private Limited — Regulatory Compliance & Quality Standards

About Svizera Labs Private Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Strip Export Data from Svizera Labs Private Limited

Strip Stats

Company Overview

Top Products by Svizera Labs Private Limited

Related Analysis

Need Detailed Export Data?

Data Source

DR LABARAN SHEHU	NIGERIA	$1.1M	22
NATIONAL TUBERCULOSIS AND LEPROSY	NIGERIA	$600.0K	12
UNOPS	MYANMAR	$100.0K	2